Crispr Therapeutics opened lower at $45.09, compared with its previous close of $45.75. In the last trading session, the stock traded between $43.02 and $45.09. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Crispr Therapeutics is now worth
$ 48.50
Resulting in a loss of
$ 51.50 (51.50%)
Invest with $1
Note: Past profits do not guarantee future returns.
Triglyceride levels fell 63% at Day 30 in severe hypertriglyceridemia patients. ANGPTL3 protein reduced by 65%, exceeding William Blair's 50% expectation. No serious adverse events or pancreatitis cases reported in the 10-patient cohort. FDA granted Regenerative Medicine Advanced Therapy designation for two indications.
2 days ago
8Nov
CRISPR Therapeutics reports 83% response rate for zugo-cel in SSc
83% of SSc patients on standard lymphodepletion achieved rCRISS-25 response at Month 3. All nine IIM patients achieved moderate or major Total Improvement Score response. No CRS above Grade 2, ICANS, or deaths reported across 21 dosed patients. Two SLE patients maintained drug-free DORIS remission through at least Month 9.
4 days ago
4Nov
Wells Fargo lowers CRISPR Therapeutics price target to $70
Wells Fargo lowered CRISPR Therapeutics price target to $70 from $75. Analyst Yanan Zhu maintained an Equal-Weight rating on the stock. The price target reduction amounts to a $5 decrease.
8 days ago
3Nov
Needham reiterates Buy on CRISPR Therapeutics, holds $82 price target
Needham reiterated a Buy rating on CRISPR Therapeutics. Price target maintained at $82 per share. Analyst Gil Blum issued the coverage update.
9 days ago
20Oct
CRISPR Therapeutics appoints A.J. Silver as CFO, effective immediately
CRISPR Therapeutics appoints A.J. Silver as CFO. Transition effective immediately, not Oct 19, 2026. Raju Prasad steps down to pursue external opportunities.
24 days ago
16Oct
UBS initiates CRISPR Therapeutics with neutral rating, $52 price target
UBS initiated coverage on CRISPR Therapeutics with a Neutral rating. Price target set at $52 per share. Coverage assigned by analyst Joon Lee.
